Antiphospholipid syndrome (APS) is an immune-mediated acquired disorder characterized by venous, arterial or small vessels thromboses and/or obstetrical morbidity, and the persistent presence of antiphospholipid antibodies (APL). APS is also associated with other “non-criteria” manifestations [1], of which thrombocytopenia is the most frequent, present in up to 29% of SLE-associated APS patients [2].Thrombocytopenia is thought to be due to peripheral platelet consumption and/or destruction subsequently to their activation by APL.
